IHM
MYOV

Iguana Healthcare Management’s Myovant Sciences Ltd. MYOV Stock Holding History

Iguana Healthcare Management’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-50,000
Closed -$622K – 82
2016
Q4 		$622K Buy
+50,000
New +$579K 0.37% 53

Other funds holding MYOV

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Iguana Healthcare Management's MYOV Position: Q1 2017 in Review

Iguana Healthcare Management sold out of Myovant Sciences Ltd. (MYOV) in Q1 2017, closing a stake of 50,000 shares — an estimated $622K sold.

Iguana Healthcare Management first reported a position in MYOV in Q4 2016 and held it in 1 quarter. The position peaked at $622K in Q4 2016. 48 funds tracked by Wall St. Rank hold MYOV as of Q1 2017.

  • Iguana Healthcare Management reported no remaining Myovant Sciences Ltd. position as of Q1 2017 after selling out during the quarter.
  • Iguana Healthcare Management sold 50,000 Myovant Sciences Ltd. shares in Q1 2017, an estimated $622K.
  • Iguana Healthcare Management first reported a position in Myovant Sciences Ltd. in Q4 2016 and held it in 1 quarter.
  • Iguana Healthcare Management's Myovant Sciences Ltd. position peaked at $622K in Q4 2016.
  • 48 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2017.

Based on Iguana Healthcare Management's 13F filing for Q1 2017, filed 15 May 2017.